Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Leukemia, Myeloid, Acute 35Advanced Solid Tumors 20Carcinoma, Non-Small-Cell Lung 14Myelodysplastic Syndromes 13Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Neoplasm Metastasis 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

Injections 4toripalimab 2Carboplatin 2aflutinib 1Pemetrexed 1Paclitaxel 1Etoposide 1Docetaxel 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Advanced Lung Cancer × Injections × 1 year × Clear all
NCT07309276 2026-05-18

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 2 Recruiting
864 enrolled
Thoracic

Advanced Lung Cancer

NCT07367529 2026-05-05

A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Recruiting
465 enrolled
Thoracic

Advanced Lung Cancer

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Completed
119 enrolled
Thoracic

Advanced Lung Cancer

NCT07229599 2025-11-17

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer

Minghui Pharmaceutical (Hangzhou) Ltd

Phase 1/2 Recruiting
300 enrolled
Thoracic

Advanced Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡